AK Medical Holdings Limited provided earnings guidance for the year ended December 31, 2019. For the year, the company expected to record a significant increase in revenue by over 50% for the year ended 31 December 2019 as compared to the revenue for the year ended 31 December 2018; and the Board expected to record a significant increase in profit attributable to equity shareholders by over 80% for the year ended 31 December 2019 as compared to the profit attributable to equity shareholders for the year ended 31 December 2018. The increase in revenue for the year ended 31 December 2019 was primarily due to the strong demand of the China market led by further penetration of the performing of joint surgeries into more hospitals in the mainland China and the Group's brand advantage built by its leading technology and high quality products. Especially, as the technology and quality of the products produced by domestic Chinese companies continuously improved, the products of the Group acquired certain market share from products of foreign brands. Besides the reasons for the increase in revenue above, the increase in profit attributable to equity shareholders for the year ended 31 December 2019 was primarily due to the effect of economies of scale and by taking effective costs control measures.